KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Capital Expenditures (2017 - 2024)

Bionano Genomics' Capital Expenditures history spans 4 years, with the latest figure at $77000.0 for Q2 2024.

  • For Q2 2024, Capital Expenditures rose 130.08% year-over-year to $77000.0; the TTM value through Mar 2025 reached $77000.0, down 94.33%, while the annual FY2024 figure was $103000.0, 93.91% down from the prior year.
  • Capital Expenditures for Q2 2024 was $77000.0 at Bionano Genomics, up from $26000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.1 million in Q2 2022 and bottomed at -$767000.0 in Q4 2022.
  • The 3-year median for Capital Expenditures is $77000.0 (2024), against an average of $209333.3.
  • The largest YoY upside for Capital Expenditures was 477.58% in 2023 against a maximum downside of 123.7% in 2023.
  • A 3-year view of Capital Expenditures shows it stood at -$767000.0 in 2022, then skyrocketed by 197.13% to $745000.0 in 2023, then crashed by 89.66% to $77000.0 in 2024.
  • Per Business Quant, the three most recent readings for BNGO's Capital Expenditures are $77000.0 (Q2 2024), $26000.0 (Q1 2024), and $745000.0 (Q4 2023).